Imagine a smart, injectable gel that acts like a biological bridge for torn tendons. Once inside the body, it can be shaped and guided using magnets or electricity to pull in the body's own healing cells. It essentially acts as a scaffold that helps the body rebuild its own tissue faster and more effectively.
Current tendon and ligament treatments lack a universal solution for diverse injury types, often requiring invasive surgery and resulting in poor recovery in complex cases.
An electromagnetic-responsive 4D nanocomposite fibrous hydrogel medical device and a GMP-validated production process.
If you are a manufacturer dealing with the lack of versatile solutions for the 33 million annual musculoskeletal injuries — this project developed a 4D nanocomposite fibrous hydrogel that provides a high-performance alternative to traditional grafts.
If you are a biotech firm dealing with low cell recruitment in tendon repairs — this project developed a device that amplifies cell homing and extracellular matrix production to replace compromised tissue.
If you are a tool provider dealing with the complexity of anchoring tendon grafts — this project developed an injectable, electromagnetic-responsive system that allows for easier anchoring via minimally invasive surgery.
Based on available project data, specific pricing is not mentioned, but the project focuses on developing business models and exploitation plans for the transfer of products.
The project includes a GMP validated production process and an industrially-driven scale-up strategy to ensure the device can be manufactured at volume.
The project aims to create business models and exploitation plans specifically for the transfer of the TEN4CARE products to the market.
The consortium is developing an early regulatory planning phase and a detailed regulatory roadmap for the sector and implied communities.
The project runs from 2025-09-01 to 2029-08-31, suggesting that market-ready outputs will be targeted toward the end of this period.
The consortium is well-balanced for commercialization, consisting of 16 partners across 7 countries. With a 31% industry ratio (5 industrial partners, including 4 SMEs), there is a strong bridge between the 4 universities and 5 research centers, ensuring that the GMP validation and scale-up strategies are grounded in industrial reality.
Contact Universita Degli Studi di Pavia
Contact us to connect with the TEN4CARE consortium for early licensing opportunities.
